Characteristic | Treatment group | P value | |
---|---|---|---|
GXST (n = 143) | Placebo (n = 144) | ||
Demographics | |||
Gender (M/F) | (73/70) | (82/62) | 0.16 |
Age (years) | 56.6 ± 8.1 | 55.3 ± 8.3 | 0.15 |
Height (cm) | 166.6 ± 7.7 | 167.5 ± 7.7 | 0.31 |
Weight (kg) | 68.9 ± 10.2 | 68.9 ± 9.8 | 1.00 |
HR (beats/min) | 71.2 ± 9.3 | 70.7 ± 9.3 | 0.64 |
SBP (mmHg) | 128.8 ± 9.7 | 129.0 ± 9.2 | 0.90 |
DBP (mmHg) | 80.9 ± 7.2 | 80.1 ± 7.7 | 0.41 |
Baseline characteristics | |||
Angina frequency (no. of events per week) | 9.4 ± 3.2 | 9.0 ± 3.0 | 0.32 |
NTG consumption (no. of pills per week) | 5.8 ± 3.5 | 5.5 ± 3.0 | 0.49 |
SAQ score Physical limitations Angina stability Angina frequency Treatment satisfaction QOL | 46.8 ± 10.6 51.8 ± 11.1 51.8 ± 8.7 36.9 ± 20.0 46.5 ± 18.2 44.4 ± 19.5 | 48.2 ± 12.0 54.1 ± 12.0 51.0 ± 9.1 43.6 ± 21.1 47.5 ± 19.2 45.0 ± 20.4 | 0.28 0.08 0.42 0.09 0.64 0.81 |
ETT Time to onset of chest pain (s) | 430.24 ± 177.2 | 456.42 ± 188.72 | 0.71 |
Time to 1 mm ST-depression (s) | 235.95 ± 153.11 | 237.69 ± 174.34 | 0.96 |
Concomitant medication | |||
β-blocker | 10 (7.0%) | 15 (10.4) | 0.15 |
ACEI | 3 (2.1%) | 0 (0.0%) | 0.06 |
ARB | 10 (7.0%) | 8 (5.6%) | 0.31 |
CCB | 10 (7.0%) | 9 (6.3%) | 0.40 |
Stains | 126 (88.1%) | 125 (86.8%) | 0.38 |
Anti-platelet agents | 138 (96.5%) | 140 (97.2%) | 0.41 |